Altor BioScience Announces a Phase 1b/2 Clinical Trial of IL-15 Superagonist ALT-803 in Combination with Anti-PD-1 Antibody Therapy for Advanced / Metastatic Non-Small Cell Lung Ca

Altor BioScience Announces a Phase 1b/2 Clinical Trial of IL-15 Superagonist ALT-803 in Combination with Anti-PD-1 Antibody Therapy for Advanced / Metastatic Non-Small Cell Lung Ca

Altor BioScience Corporation (Altor), a leading developer of cancer immunotherapeutics, announced enrollment is complete for the first cohort in a Phase 1b/2 trial using ALT-803, a proprietary interleukin-15 (IL-15) superagonist protein complex, in combination with the approved anti-PD-1 antibody (Ab) nivolumab (Opdivo®; Bristol-Myers Squibb) for patients with pre-treated, advanced, or metastatic non-small cell lung cancer (NSCLC). This Investigator-Sponsored Trial is being conducted under the direction of John Wrangle, M.D., M.P.H., at the Medical University of South Carolina (MUSC).

Read More

Cancer MoonShot 2020 and NantHealth Form Collaborative Melanoma and Sarcoma Working Group with Columbia University and UPMC to Accelerate Personalized Immunotherapy

Cancer MoonShot 2020 and NantHealth announced the formation of the Melanoma and Sarcoma Working Group to accelerate molecular-informed immunotherapy trials and to focus on identifying the most effective, cancer-directed immunotherapy treatments for patients with melanoma and sarcoma.

Read More

NantHealth Announces Commercial Availability of GPS Cancer™ and Launch of GPS Cancer Browser on a Secure Mobile Platform at the 2016 American Society of Clinical Oncology Annual Meeting

NantHealth, Inc. (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, announced today the commercial availability of Genomic Proteomic Spectrometry Cancer, or GPS Cancer. Read the full press release HERE.

Read More

Dr. Patrick Soon-Shiong Shares Promising Results of Novel Adenoviral Colon Cancer Vaccine in Treating End-Stage Colon Cancer

Dr. Patrick Soon-Shiong CEO of NantWorks and founder of Cancer Moonshot 2020, announced that a novel genetically engineered adenovirus vaccine designed to treat colon cancer showed, in Phase II testing, a more than doubling of survival rate, with little to no toxicity. Promising results show some patients alive now more than five years after receiving the colon vaccine while on no other therapy.

Read full press release here.

NantHealth Announces New Expanded Coverage of GPS Cancer Test with Self-Insured Employers, ‎ Insurance Payers, and Health Systems

NantHealth, LLC, announced the expanded adoption of GPS Cancer, a unique comprehensive molecular test to help oncology care providers guide treatment strategies for cancer care, by partnering with major self-insurers that have agreed to cover the costs for their employees requiring this test. Bank of America, Phoenix Children’s Hospital, Sanford Health will become the first national and regional self-insured employers to cover next-generation whole genome sequencing and proteomics for various cancers.

Read full press release here.

At Vatican, Biden speaks of faith and calls for global coordination against cancer

At Vatican, Biden speaks of faith and calls for global coordination against cancer

U.S. Vice President Joe Biden and Pope Francis made separate but similar calls for better global coordination, research and care in treatment of cancer at a Vatican event Friday in an evocative and unprecedented collaboration of political and religious efforts to mitigate the disease.

Speaking one after another in front of a massive bronze depiction of Christ's resurrection in the Vatican's Paul VI Hall, both Biden and Francis used spiritual imagery to push the world to action during a regenerative medicine conference.

Read More